Search Result

Results for "

human CD19 B-cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD19 (6) CD28 (1) CD3 (1) ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) IFNAR (1) Interleukin Related (1) mRNA (1) TNF Receptor (1)
By Research Areas:	Cancer (5) Inflammation/Immunology (2)
Oligonucleotides:	CAR-T (1) mRNA (1)

Inhibitors & Agonists

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: CD19 CD1 CD38 CD28 CD20 CD22 Transferrin Receptor CD3 P-selectin CD6 CD2 CD276/B7-H3 CD73 c-Kit LAG-3 L-Selectin CTLA-4 CD47 ALCAM/CD166 Neprilysin E-Selectin Scavenger Receptor Class B type I (SR-BI） FLT3 Tim3 CD44 Anaplastic lymphoma kinase (ALK) CD74 Human leukocyte immunoglobulin (Ig)-like receptors (LILR) P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-153084A

CD19 CAR mRNA (Human) 1 Publications Verification	mRNA CD19	Cancer
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-P991176

RG-6333 RO7443904	CD19 CD28	Cancer
RG-6333 is a bispecific agonist targeting *CD19* and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) .

HY-P991900

LY3541860	CD19	Inflammation/Immunology
LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (K_d values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC₅₀ = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .

HY-P991899

IKS03 Antibody LCB73 Antibody	ADC Antibody CD19	Cancer
IKS03 Antibody (LCB73 Antibody) is an anti-human *CD19* antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .

HY-P991898

IASO-782 RD126	CD19	Inflammation/Immunology
IASO-782 (RD126) is a fully human monoclonal antibody targeting human *CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells*. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Cat. No.	Product Name	Target	Research Area	Image

HY-P99349

Loncastuximab tesirine Loncastuximab tesirine-lpyl; ADCT-402	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-P991176

RG-6333 RO7443904	CD19 CD28	Cancer
RG-6333 is a bispecific agonist targeting *CD19* and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG1 kappa, isotype control (HY-P99001) .

HY-P991900

LY3541860	CD19	Inflammation/Immunology
LY3541860 is a selective anti-CD19 antibody that both binds human CD19 with high affinity and selectively binds human B cells (K_d values: 76.8 pM and 94.5 nM for humans and cynomolgus monkeys, respectively). LY3541860 inhibits CpG-induced CD69 expression (IC₅₀ = 0.006 nM). LY3541860 exhibits potent B cell inhibitory activities. LY3541860 can inhibit both BCR- and TLR-induced human B cell activation. LY3541860 can be used for the research of autoimmune diseases .

HY-P991899

IKS03 Antibody LCB73 Antibody	ADC Antibody CD19	Cancer
IKS03 Antibody (LCB73 Antibody) is an anti-human *CD19* antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .

HY-P991898

IASO-782 RD126	CD19	Inflammation/Immunology
IASO-782 (RD126) is a fully human monoclonal antibody targeting human *CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells*. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Cat. No.	Product Name		Classification

HY-153084A

CD19 CAR mRNA (Human) 1 Publications Verification		mRNA CAR-T
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.